Spots Global Cancer Trial Database for non hodgkin's lymphoma
Every month we try and update this database with for non hodgkin's lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Chidamide Bridging for CAR-T Therapy | NCT05370547 | Non Hodgkin's L... | Chidamide Fludarabine and... Anti-CD19 CAR-T... | 16 Years - 75 Years | Chinese PLA General Hospital | |
| Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | NCT04796675 | Acute Lymphocyt... Chronic Lymphoc... Non Hodgkin's L... | Fludarabine + C... | 18 Years - | Wuhan Union Hospital, China | |
| Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy | NCT01018758 | Chemotherapy-In... Non Hodgkin's L... | Palonosetron | 18 Years - | Gruppo Italiano Studio Linfomi | |
| Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | NCT04402138 | Mantle Cell Lym... | Acalabrutinib | 18 Years - | SCRI Development Innovations, LLC | |
| Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL | NCT05554939 | Non Hodgkin's L... | Allogenic CD19-... Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Chinese PLA General Hospital | |
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | NCT00013533 | Hodgkin Lymphom... Lymphocytic Leu... Mixed Cell Leuk... Myelodysplastic... Non Hodgkin's L... CML ALL AML Lymphoma | Stem cell trans... | 4 Years - 20 Years | National Institutes of Health Clinical Center (CC) | |
| Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL | NCT01527422 | Lymphoma Non Hodgkin's L... | Cyclophosphamid... | 18 Years - | Auxilio Mutuo Cancer Center | |
| Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | NCT00597714 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | Non-myeloablati... | 18 Years - | Duke University | |
| CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation | NCT00038818 | Chronic Myeloge... Multiple Myelom... Non Hodgkin's L... Hodgkin's Disea... Chronic Lymphoc... | CD8 Depleted Do... | - | M.D. Anderson Cancer Center | |
| Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant | NCT01904175 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | 18 Years - | Duke University | ||
| Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B | NCT00926757 | Non Hodgkin's L... Hepatitis B | Entecavir proph... Therapeutic ent... | 16 Years - | Taipei Veterans General Hospital, Taiwan | |
| A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas | NCT00001430 | Hodgkin's Disea... Non Hodgkin's L... | PBSC IL-2 EPOCH II | - | National Institutes of Health Clinical Center (CC) | |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | NCT01342289 | Hodgkin's Lymph... Leukemia Myelodysplastic... Multiple Myelom... Non Hodgkin's L... | Cyclophosphamid... Fludarabine Total body irra... Mycophenolate M... Tacrolimus 60 Tacrolimus 90 Tacrolimus 120 Bone marrow tra... | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma | NCT00994643 | High Risk Non-H... | Rituximab Interleukin-2 | 18 Years - | Thomas Jefferson University | |
| Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) | NCT06285422 | Non Hodgkin's L... Large B-cell Ly... | SC262 | 18 Years - 80 Years | Sana Biotechnology | |
| Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | NCT00001830 | Chronic Lymphoc... Graft vs Host D... Hodgkin's Disea... Multiple Myelom... Non Hodgkin's L... | Th2 cells in al... Th2 Cells | 12 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) | NCT01610180 | Purpura, Thromb... Autoimmune Thro... Autoimmune Thro... Chronic Lymphoc... Non Hodgkin's L... | Eltrombopag Ola... | 18 Years - | Fondazione Progetto Ematologia | |
| Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT01325701 | Diffuse Large C... | ibrutinib | 18 Years - | Pharmacyclics LLC. | |
| TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL | NCT06014073 | Non Hodgkin's L... | TRAC and Power3... Fludarabine Cyclophosphamid... | 18 Years - 70 Years | Chinese PLA General Hospital | |
| Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination | NCT02007811 | Acute Myeloid L... Acute Lymphobla... Chronic Myeloid... Non Hodgkin's L... Hodgkin's Disea... Myelodysplastic... Multiple Myelom... Aplastic Anemia | allogeneic dono... | 18 Years - 75 Years | University of Erlangen-Nürnberg Medical School | |
| Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma | NCT00994643 | High Risk Non-H... | Rituximab Interleukin-2 | 18 Years - | Thomas Jefferson University | |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | NCT01101581 | Non Hodgkin's L... NHL Aggressive NHL Diffuse Large B... | Veltuzumab and ... 90Y-epratuzumab... veltuzumab | 18 Years - | Gilead Sciences | |
| Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases | NCT00038857 | Leukemia Lymphoma | Megadose of CD3... Melphalan Thiotepa Fludarabine Rabbit ATG | - 55 Years | M.D. Anderson Cancer Center | |
| Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | NCT04402138 | Mantle Cell Lym... | Acalabrutinib | 18 Years - | SCRI Development Innovations, LLC | |
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | NCT00013533 | Hodgkin Lymphom... Lymphocytic Leu... Mixed Cell Leuk... Myelodysplastic... Non Hodgkin's L... CML ALL AML Lymphoma | Stem cell trans... | 4 Years - 20 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL | NCT00477945 | Non Hodgkin's L... | clofarabine | 18 Years - 70 Years | Indiana University | |
| Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL | NCT01527422 | Lymphoma Non Hodgkin's L... | Cyclophosphamid... | 18 Years - | Auxilio Mutuo Cancer Center | |
| Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00323934 | Tumors Non Hodgkin's L... | MGCD0103 | 18 Years - | Mirati Therapeutics Inc. | |
| Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers | NCT01135329 | Lymphoma Leukemia Myelodysplastic... | Fludarabine Busulfan Cyclophosphamid... Mycophenolate M... Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma | NCT04497688 | Non Hodgkin's L... | PEG-rhG-CSF | 18 Years - | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | |
| Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) | NCT01610180 | Purpura, Thromb... Autoimmune Thro... Autoimmune Thro... Chronic Lymphoc... Non Hodgkin's L... | Eltrombopag Ola... | 18 Years - | Fondazione Progetto Ematologia | |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | NCT01342289 | Hodgkin's Lymph... Leukemia Myelodysplastic... Multiple Myelom... Non Hodgkin's L... | Cyclophosphamid... Fludarabine Total body irra... Mycophenolate M... Tacrolimus 60 Tacrolimus 90 Tacrolimus 120 Bone marrow tra... | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | NCT01101581 | Non Hodgkin's L... NHL Aggressive NHL Diffuse Large B... | Veltuzumab and ... 90Y-epratuzumab... veltuzumab | 18 Years - | Gilead Sciences | |
| Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma | NCT00834951 | Non Hodgkin's L... | Low dose total ... | 60 Years - | University of Aarhus | |
| Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant | NCT01321541 | Diffuse Large B... de Novo DLBCL DLBCL Transform... Follicular Grad... | Pixantrone + Ri... Gemcitabine + R... | 18 Years - | CTI BioPharma | |
| Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant | NCT01904175 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | 18 Years - | Duke University | ||
| Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | NCT06285422 | Non Hodgkin's L... Large B-cell Ly... | SC262 | 18 Years - 80 Years | Sana Biotechnology | |
| Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | NCT00597714 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | Non-myeloablati... | 18 Years - | Duke University | |
| Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant | NCT01904175 | Hodgkin's Disea... Non Hodgkin's L... Myeloma Leukemia Myelodysplasia | 18 Years - | Duke University | ||
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | NCT01101581 | Non Hodgkin's L... NHL Aggressive NHL Diffuse Large B... | Veltuzumab and ... 90Y-epratuzumab... veltuzumab | 18 Years - | Gilead Sciences | |
| Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | NCT00001830 | Chronic Lymphoc... Graft vs Host D... Hodgkin's Disea... Multiple Myelom... Non Hodgkin's L... | Th2 cells in al... Th2 Cells | 12 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy | NCT01018758 | Chemotherapy-In... Non Hodgkin's L... | Palonosetron | 18 Years - | Gruppo Italiano Studio Linfomi | |
| Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | NCT04796675 | Acute Lymphocyt... Chronic Lymphoc... Non Hodgkin's L... | Fludarabine + C... | 18 Years - | Wuhan Union Hospital, China | |
| Positron Emission Tomography(PET) in Lymphoma Assessment | NCT00887718 | Hodgkin's Lymph... Non Hodgkin's L... | PET Scan | 18 Years - | University Health Network, Toronto | |
| Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant | NCT00909948 | Non Hodgkin's L... Hodgkin Disease Multiple Myelom... | Fludarabine and... Total body irra... | 18 Years - 75 Years | Massachusetts General Hospital | |
| Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies | NCT00460694 | Acute Myeloid L... Acute Lymphobla... Chronic Myeloid... Non Hodgkin's L... Hodgkin's Disea... Myelodysplastic... Multiple Myelom... | infusion of all... | 12 Years - 60 Years | Singapore General Hospital | |
| Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT01325701 | Diffuse Large C... | ibrutinib | 18 Years - | Pharmacyclics LLC. | |
| Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma | NCT00967044 | Lymphoma | Panobinostat Everolimus | 18 Years - | M.D. Anderson Cancer Center | |
| Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B | NCT00926757 | Non Hodgkin's L... Hepatitis B | Entecavir proph... Therapeutic ent... | 16 Years - | Taipei Veterans General Hospital, Taiwan | |
| Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL | NCT05554939 | Non Hodgkin's L... | Allogenic CD19-... Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Chinese PLA General Hospital | |
| Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma | NCT04402138 | Mantle Cell Lym... | Acalabrutinib | 18 Years - | SCRI Development Innovations, LLC | |
| Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant | NCT00909948 | Non Hodgkin's L... Hodgkin Disease Multiple Myelom... | Fludarabine and... Total body irra... | 18 Years - 75 Years | Massachusetts General Hospital | |
| BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL) | NCT01063439 | Non Hodgkin's L... | Busulfan, Etopo... | - 65 Years | Inje University | |
| Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers | NCT01135329 | Lymphoma Leukemia Myelodysplastic... | Fludarabine Busulfan Cyclophosphamid... Mycophenolate M... Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | NCT04796675 | Acute Lymphocyt... Chronic Lymphoc... Non Hodgkin's L... | Fludarabine + C... | 18 Years - | Wuhan Union Hospital, China | |
| Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL | NCT05554939 | Non Hodgkin's L... | Allogenic CD19-... Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Chinese PLA General Hospital | |
| Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | NCT01101581 | Non Hodgkin's L... NHL Aggressive NHL Diffuse Large B... | Veltuzumab and ... 90Y-epratuzumab... veltuzumab | 18 Years - | Gilead Sciences | |
| Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT01325701 | Diffuse Large C... | ibrutinib | 18 Years - | Pharmacyclics LLC. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
